Laura M. Nadeau
Expertise in
45
conditions

Dr. Laura M. Nadeau

Hematology | Oncology
3577 West 13 Mile Road, Suite 103, 
Royal Oak, MI 
On Staff At
Accepting New Patients
Offers Telehealth
27 Years of Experience
Expertise in
45
conditions
3577 West 13 Mile Road, Suite 103, 
Royal Oak, MI 

Overview

Laura Nadeau is a Hematologist and an Oncologist in Royal Oak, Michigan. Dr. Nadeau has been practicing medicine for over 27 years is highly rated in 45 conditions, according to our data. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Adult Immune Thrombocytopenia, Chronic Familial Neutropenia, and Bone Marrow Aspiration. Dr. Nadeau is currently accepting new patients.

Her clinical research consists of co-authoring 8 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Case Western Reserve University, 1999

Residency

University Hospitals Case Medical Center

Specialties

Hematology
Oncology

Licenses

Internal Medicine in MI

Board Certifications

American Board Of Internal Medicine
American Board Of Internal Medicine
American Board Of Internal Medicine

Fellowships

St. Vincent Charity Hospital

Hospital Affiliations

Corewell Health William Beaumont University Hospital
Corewell Health Beaumont Troy Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Hematology Oncology Consultants Division of Michigan Healthcare Professionals PC
3577 West 13 Mile Road, Suite 103, Royal Oak, MI 48073
Other Locations
Hematology Oncology Consultants
4550 Investment Drive, Suite B120, Troy, MI 48098

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: December 30, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Other
Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib
Study Phase: Phase 2
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
A Phase 2 Study of Duvelisib Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi)
A Phase 2 Study of Duvelisib Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi)
Enrollment Status: Withdrawn
Publish Date: February 28, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 19, 2022
Intervention Type: Drug, Procedure
Study Drugs: Fluorouracil, Gemcitabine hydrochloride, Irinotecan hydrochloride, Oxaliplatin, Paclitaxel albumin-stabilized nanoparticle formulation
Study Phase: Phase 2
View 5 Less Clinical Trials

8 Total Publications

Case Report: Androgen receptor-positive, locoregionally advanced breast cancer in a transgender man and an update on breast cancer management in a gender-diverse patient population.
Case Report: Androgen receptor-positive, locoregionally advanced breast cancer in a transgender man and an update on breast cancer management in a gender-diverse patient population.
Journal: Frontiers in oncology
Published: June 25, 2025
Similar Doctors
Expertise in
31
conditions
Dr. Kelly Walkovich
Hematology | Oncology
Expertise in
31
conditions
Dr. Kelly Walkovich
Hematology | Oncology

University Of Michigan Medical Center

1500 E Medical Center Dr, 
Ann Arbor, MI 
 (35.5 miles away)
734-936-9814
Languages Spoken:
English
See accepted insurances

Kelly Walkovich is a Hematologist and an Oncologist in Ann Arbor, Michigan. Dr. Walkovich is highly rated in 31 conditions, according to our data. Her top areas of expertise are Hemophagocytic Lymphohistiocytosis, Infantile Neutropenia, Non-Langerhans-Cell Histiocytosis, and Reticulohistiocytoma.

Expertise in
5
conditions
Dr. Steven Pipe
Hematology | Oncology
Expertise in
5
conditions
Dr. Steven Pipe
Hematology | Oncology

University Of Michigan Medical Center

1500 E Medical Center Dr, 
Ann Arbor, MI 
 (35.5 miles away)
734-936-4000
Languages Spoken:
English
See accepted insurances

Steven Pipe is a Hematologist and an Oncologist in Ann Arbor, Michigan. Dr. Pipe is highly rated in 5 conditions, according to our data. His top areas of expertise are Hemophilia A, Hemophilia B, Blood Clots, and Von Willebrand Disease (VWD).

Expertise in
5
conditions
Dr. Emily Meier
Hematology | Oncology
Expertise in
5
conditions
Dr. Emily Meier
Hematology | Oncology

DMC Children's Hospital Of Michigan

3901 Beaubien St, 
Detroit, MI 
 (17.4 miles away)
313-745-5437
Languages Spoken:
English
See accepted insurances

Emily Meier is a Hematologist and an Oncologist in Detroit, Michigan. Dr. Meier is highly rated in 5 conditions, according to our data. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Laura M. Nadeau

How do I make an appointment with Dr. Laura M. Nadeau?

You can book an appointment with Dr. Laura M. Nadeau by calling their office at 248-288-4500. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Laura M. Nadeau a top-rated expert for Paget Disease of the Breast?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Laura M. Nadeau is classified as an Distinguished expert for Paget Disease of the Breast, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Laura M. Nadeau specialize in?

While Dr. Laura M. Nadeau is a Hematology, they have specific expertise in Paget Disease of the Breast, Breast Cancer, and Adult Immune Thrombocytopenia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Laura M. Nadeau participate in research or clinical trials?

Yes. Dr. Laura M. Nadeau has published 8 articles and abstracts on conditions like Paget Disease of the Breast. You can view a list of Dr. Laura M. Nadeau's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Laura M. Nadeau accept my insurance?

Dr. Laura M. Nadeau accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 248-288-4500 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nadeau's expertise for a condition
ConditionClose
    View All 19 Distinguished Conditions
    View All 26 Advanced Conditions
    View All 93 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile